The manufacturer of the specific Ribokis 200 mg product is Everest Pharmaceuticals Ltd..
This should be distinguished from the documented development history of ribociclib and KISQALI.
Ribociclib development
KISQALI was developed by the Novartis Institutes for BioMedical Research under a research collaboration with Astex Pharmaceuticals.
Reference medicine
KISQALI contains ribociclib and is authorized for specified breast-cancer indications. The EMA identifies Novartis Europharm Limited as its European marketing authorization holder.
Manufacturer versus developer
The company that developed a medicine is not necessarily the manufacturer of every product containing the same active ingredient.
A manufacturer, developer, brand owner, marketing authorization holder, distributor and supplier may be separate entities.
Quality information
Specific manufacturing sites, GMP certifications, batch-release facilities and regulatory quality documentation for Ribokis are Everest Pharmaceuticals Ltd..
Official company information
For the reference medicine, official Novartis information is available through the company’s corporate resources. This does not establish that Novartis manufactures Ribokis.